Optical Coherence Tomography Angiography Evaluation Of Patients Taking Hydroxychloroquine

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07409740

Enrollment

Registered

2026-02-13

Start date

2026-02-01

Completion date

2026-09-01

Last updated

2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydroxychloroquine Retinopathy

Brief summary

This study aims to evaluate retinal and choroidal microvascular changes using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy. Hydroxychloroquine is commonly used in the treatment of autoimmune diseases and may cause retinal toxicity with long-term use. OCTA is a non-invasive imaging modality that allows detailed assessment of retinal vascular changes.

Detailed description

Hydroxychloroquine is widely prescribed for the management of autoimmune and rheumatologic diseases. Long-term use of hydroxychloroquine has been associated with retinal toxicity, which may lead to irreversible visual impairment if not detected early. Conventional screening methods include fundus examination, automated visual field testing, and spectral-domain optical coherence tomography. Optical coherence tomography angiography (OCTA) is a non-invasive imaging technique that enables quantitative and qualitative assessment of retinal and choroidal microvasculature. This study is designed to evaluate OCTA parameters in patients receiving hydroxychloroquine therapy. Patients undergoing hydroxychloroquine treatment will be evaluated using OCTA imaging. Retinal vascular parameters will be analyzed and correlated with clinical variables such as duration of treatment and cumulative hydroxychloroquine dose. The findings of this study may contribute to improved understanding of early microvascular changes associated with hydroxychloroquine exposure and the potential role of OCTA in retinal toxicity screening.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adults (≥18 years old) with documented HCQ therapy for ≥1 year. * Stable systemic disease under medical supervision.

Exclusion criteria

* -patients with media opacity. * Any pre-existing retinal or optic nerve disease (e.g., diabetic retinopathy, AMD, myopic degeneration). * History of intraocular surgery or trauma. * Uncontrolled systemic vascular diseases (e.g., hypertension)

Design outcomes

Primary

Measure	Time frame	Description
Superficial Capillary Plexus Vessel Density (SCP)	Day 1	Measurement of superficial capillary plexus vessel density using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy.
Deep Capillary Plexus Vessel Density (DCP)	Day 1	Measurement of deep capillary plexus vessel density using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy.

Outcome results